FFO
KYTX icon

Fortitude Family Office’s Kyverna Therapeutics KYTX Stock Holding History

Fortitude Family Office’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-126
Closed -$1.09K – 2395
2026
Q1 		$1.09K Buy
+126
New +$1.05K ﹤0.01% 1494

Other funds holding KYTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

Fortitude Family Office's KYTX Position: Q2 2026 in Review

Fortitude Family Office sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 126 shares — an estimated $1.09K sold.

Fortitude Family Office first reported a position in KYTX in Q1 2026 and held it in 1 quarter. The position peaked at $1.09K in Q1 2026. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Fortitude Family Office reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 126 Kyverna Therapeutics shares in Q2 2026, an estimated $1.09K.
  • Fortitude Family Office first reported a position in Kyverna Therapeutics in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Kyverna Therapeutics position peaked at $1.09K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.